Prescient Therapeutics (PTX) Stock Price, News & Analysis

Company Overview

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. The company was incorporated in 1986 and is based in Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 537,831 shs
• Average Volume: N/A
• Market Capitalization: A$38.66 million
• P/E Ratio: N/A
• Dividend Yield: 5.88%
• Price Target: N/A
• Consensus Rating: N/A

PTX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Prescient Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Prescient Therapeutics investors own include NOVONIX (NVX), SkyCity Entertainment Group (SKC), KLA (KLAC), Findi (FND) and Chalice Mining (CHN).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:PTX
• CIK: N/A
• Web: www.ptxtherapeutics.com
• Phone: 61 3 9692 7222
• Fax: N/A
• Employees: 171
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$8.24 million
• Net Margins: -221.91%
• Pretax Margin: N/A
• Return on Equity: -40.50%
• Return on Assets: -18.52%

Debt

• Debt-to-Equity Ratio: 1.83
• Current Ratio: 8.08
• Quick Ratio: 17.31

Sales & Book Value

• Annual Sales: A$3.71 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 1.91
• Book Value: A$0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 805,320,000
• Free Float: N/A
• Market Cap: A$38.66 million
• Optionable: Not Optionable
• Beta: 1.19